Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

Financing Round:
Nuvig Therapeutics has closed a $161 million Series B financing round to support its preclinical pipeline and the clinical development of NVG-2089, a first-in-class recombinant Fc fragment immunomodulator1.

Lead Investors:
The financing round was co-led by Norwest Venture Partners, Sanofi Ventures, and Blue Owl Healthcare Opportunities, with participation from new and existing investors1.

Clinical Development:
NVG-2089 is advancing into Phase II trial development, targeting chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune conditions with significant treatment gaps12.

Mechanism of Action:
NVG-2089 works by binding to type II Fc receptors, leading to the expansion of regulatory T cells (Tregs) and downregulation of inflammatory pathways, offering a non-immunosuppressive treatment approach2.

Disease Target:
CIDP is a rare autoimmune disorder where the immune system attacks the protective sheath covering nerve fibers, leading to nerve and motor problems and progressively worsening muscle function12.

Competitive Landscape:
Nuvig’s approach is distinct from FcRn inhibitors like Argenx’s Vyvgart, which primarily target autoantibodies and can lead to immunosuppression, whereas NVG-2089 addresses immune cell infiltration and offers a broader immunomodulatory effect2.

Company Background:
Nuvig Therapeutics emerged from stealth in 2022 with a $47 million Series A round and is based on research from The Rockefeller University2.

Sources:

1. https://www.clinicaltrialsarena.com/news/nuvig-financing-nvg-2089/

2. https://medcitynews.com/2024/12/autoimmune-disease-startup-nuvig-therapeutics-cidp-argenx-vyvgart/